South Korea Approves First Domestically Developed COVID-19 Vaccine

SEOUL, South Korea — Health officials in South Korea on Wednesday approved the country’s first domestically developed COVID-19 vaccine for people 18 years or older, adding another public health tool in the fight against a prolonged pandemic. In clinical trials involving some 4,000 participants in South Korea and five other countries, SK Bioscience’s two-dose SKYCovione vaccine appeared to be more effective than the broadly used AstraZeneca shots in building immunity against infections, officials at South Korea’s Food and Drug Safety Ministry said. It isn’t immediately clear how officials will administer the newly developed vaccine or how big of a role the shots will have in the next phase of the pandemic. The shots were designed for the original version of the coronavirus, not the more transmissible omicron variant that wreaked havoc in the country earlier this year. U.S. vaccine giants Pfizer and Moderna have been speeding up their development of booster shots targeting omicron and experts say it’s possible the virus could evolve again in the coming months. [time-brightcove not-tgx=”true”] Read more: An FDA Panel Decides It’s Time For New COVID-19 Boosters South Korea’s mass immunization campaign has been mainly dependent on Pfizer and Moderna’s mRNA shots. But officials say protein vaccines like SKYCovione, which are similar to shots used for years against the common flu and hepatitis B, could appeal to peopl...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 overnight wire Source Type: news